Chemed (CHE) to Release Earnings on Wednesday

Chemed (NYSE:CHE) is expected to be issuing its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect the company to announce earnings of $7.02 per share and revenue of $659.0860 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 10:00 AM ET.

Chemed Trading Down 0.1%

Chemed stock opened at $472.95 on Wednesday. The firm has a market cap of $6.70 billion, a PE ratio of 25.01, a P/E/G ratio of 2.30 and a beta of 0.44. Chemed has a 12 month low of $408.42 and a 12 month high of $623.60. The stock’s 50 day simple moving average is $442.13 and its two-hundred day simple moving average is $442.72.

Chemed Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, March 13th. Investors of record on Monday, February 23rd will be issued a dividend of $0.60 per share. The ex-dividend date of this dividend is Monday, February 23rd. This represents a $2.40 dividend on an annualized basis and a yield of 0.5%. Chemed’s dividend payout ratio is 12.69%.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Zacks Research upgraded shares of Chemed from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 30th. Jefferies Financial Group lowered shares of Chemed from a “buy” rating to a “hold” rating in a research note on Thursday, January 22nd. Royal Bank Of Canada cut their price target on Chemed from $589.00 to $572.00 and set an “outperform” rating for the company in a research note on Monday, November 10th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Chemed in a report on Wednesday, January 21st. Three equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $555.50.

Insider Activity at Chemed

In related news, CEO Kevin J. Mcnamara sold 2,000 shares of the firm’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $437.55, for a total value of $875,100.00. Following the transaction, the chief executive officer directly owned 94,197 shares of the company’s stock, valued at approximately $41,215,897.35. This trade represents a 2.08% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 3.29% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Chemed

A number of hedge funds have recently made changes to their positions in CHE. AQR Capital Management LLC lifted its position in shares of Chemed by 89.2% in the fourth quarter. AQR Capital Management LLC now owns 325,579 shares of the company’s stock valued at $139,302,000 after acquiring an additional 153,469 shares in the last quarter. Victory Capital Management Inc. raised its stake in Chemed by 1,260.2% in the 4th quarter. Victory Capital Management Inc. now owns 117,685 shares of the company’s stock valued at $50,353,000 after purchasing an additional 109,033 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in Chemed by 740.9% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 95,573 shares of the company’s stock valued at $42,792,000 after purchasing an additional 84,208 shares in the last quarter. Epoch Investment Partners Inc. lifted its holdings in Chemed by 29.4% in the 3rd quarter. Epoch Investment Partners Inc. now owns 307,275 shares of the company’s stock valued at $137,579,000 after purchasing an additional 69,878 shares in the last quarter. Finally, UBS Group AG boosted its stake in Chemed by 104.2% during the 3rd quarter. UBS Group AG now owns 112,118 shares of the company’s stock worth $50,200,000 after purchasing an additional 57,201 shares during the last quarter. Institutional investors and hedge funds own 95.85% of the company’s stock.

Chemed Company Profile

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.